Screening

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology

Recent advances in mass spectrometry for drug discovery and development

Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical and biological entities. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Pharmacology #RNA #Screening #Stem cells #System biology #Systems biology

PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology

PATCHERS vs SCREENERS: divergent opinion on high throughput electro-physiology By Dr John Comley The prospect of enabling higher throughput electro-physiology (patch-clamping) has created much expectation from scientists within the ion channel community. Yet there are opposing views among traditional electro-physiologists and screeners as to the needed specification and the preferred… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Lead discovery #Orphan drugs #Regulatory #RNA #Screening

Biotechnology-based Orphan Drugs – Achievements and challenges

Biotechnology-based Orphan Drugs - Achievements and challenges By Dr Erik Tambuyzer For many patients suffering from rare diseases, there are simply no medicines available to treat their condition. With an estimated 20-30 million such patients in Europe alone, rare diseases collectively represent a significant unmet medical need. Individual disease groups,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell culture #Cellular assays #Drug development #Drug discovery #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #RNA #Screening #Stem cells

The Industrial Evolution of Screening Infrastructure

The Industrial Evolution of Screening Infrastructure By Chris Molloy Industrialisation of screening depends upon the use of a stable,mature infrastructure. According to a recent Boston Consulting Group report, a pharmaceutical company needs to spend 900 million ($810 million) on R&D to bring a product to market. This is almost three… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Cellular assays #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Organic chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #Target validation

Synthetic approaches to rational drug design – A changing landscape

Synthetic approaches to rational drug design - A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming the bottleneck… Read More

#Archive

High-throughput screening
#Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #High throughput screening #Imaging #Lead discovery #RNA #Screening #Target validation

ASSAY INTERFERENCE – A limiting factor in HTS?

ASSAY INTERFERENCE - A limiting factor in HTS? By Dr John Comley With current HTS focused on better quality hits, the necessity to differentiate between true and false results puts increasing emphasis on the robustness of the assay technology. This article explores the common causes of assay interference, the effect… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Protein chemistry / Proteomics #Screening #Sequencing #System biology #Systems biology #Therapeutics

The cost and value of three-dimensional protein structure

The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components, and the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Imaging #Lead discovery #Medicinal chemistry #Organic chemistry #Orphan drugs #PCR #Pharmacology #RNA #Screening #Stem cells #System biology #Target validation

High Throughput Screening using G-protein coupled receptors as the target plate-based and biochromatographic technologies

High Throughput Screening using G-protein coupled receptors as the target plate-based and biochromatographic technologies By Professor Irving W.Wainer, Dr Farideh Beigi and Dr Ruin Moaddel The G-protein coupled receptor (GPCR) family constitutes the largest class of cell surface receptors and GPCRs are the targets for more than 50% of the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Molecular pathology and the art of drug design

Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Protein Biochip Content Problem

The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

RNA interference – A technology platform for target validation, drug discovery and therapeutic development

RNA interference - A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'. As we advance in the 'functional omics' arena… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Immunology #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Organic chemistry #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Functional proteomics in drug discovery

Functional proteomics in drug discovery By Dr Stefan W. Henning and Dr Leodevico L. Ilag The critical bottleneck of the drug discovery process is developing the right drug for the right target. Today proteins represent more than 90% of druggable targets and will most likely remain the single most important… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #RNA #Screening

In Silico Structure-based Drug Design – Shifting the bottleneck?

In Silico Structure-based Drug Design - Shifting the bottleneck? By Dr Jonathan Heal Drug Discovery The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. Indeed many pharma companies have already adopted some type of virtual screening capability to complement… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #PCR #Pharmokinetics #RNA #Screening

Surface Plasmon Resonance’s impact on drug discovery – resolution, throughput and versatility

Surface Plasmon Resonance's impact on drug discovery - resolution, throughput and versatility By Dr David G. Myszka and Dr Rebecca L. Rich Surface plasmon resonance (SPR) biosensors have rapidly become a standard tool within the pharmaceutical and biotechnology industries. Label-free, real-time measurements are the calling card for this technology, which… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Pathology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Target validation #Therapeutics

The role of ZEBRAFISH in drug discovery

The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have… Read More

#Archive